Characteristics of the 20 patients
| Characteristic . | Value . |
|---|---|
| Age (range), y | 35.5 (16-61) |
| Male sex, no. (%) | 9 (45) |
| Pretreatment | |
| WBC count (range), ×109/L | 32.9 (10.6-140.8) |
| Platelet count (range), ×109/L | 32.5 (5-74) |
| Blasts of bone marrow (range), % | 90 (34-97.5) |
| PML-RARA/ABL (range), % | 37.6 (20.1-92.4) |
| Type of transcript (L/S/V) | 10/7/3 |
| Fibrinogen (range), mg/dL | 163 (60-429) |
| D-dimer (range), μg/L | 9 296 (2 570 to >20 000) |
| Cytogenetics, no. (%) | |
| Solo t (15;17) | 15 (75) |
| Others | 5 (25) |
| Induction treatment | |
| Live damage, no. (%) | |
| 1 grade | 2 (10) |
| 2 grade | 7 (35) |
| 3-4 grade | 0 (0) |
| Differentiation syndromes, no. (%) | |
| Moderate | 4 (20) |
| Severe | 3 (15) |
| Platelet infusion (range), U | 5 (1-18) |
| Red blood infusion (range), U | 8 (0-12) |
| Hospital days (range) | 25 (4-37) |
| Achieving hematologic CR, no. (range) | 20 (100) |
| Days to achieving hematologic CR (range) | 30 (28-55) |
| Postremission follow-up | |
| Achieving CMR, no. (%) | 20 (100) |
| Days to achieving CMR (range) | 90 (42-132) |
| Continue CMR, no. (%) | 18 (90) |
| Molecular relapse, no. (%) | 2 (10) |
| Hematologic relapse, no. (%) | 0 (0) |
| Characteristic . | Value . |
|---|---|
| Age (range), y | 35.5 (16-61) |
| Male sex, no. (%) | 9 (45) |
| Pretreatment | |
| WBC count (range), ×109/L | 32.9 (10.6-140.8) |
| Platelet count (range), ×109/L | 32.5 (5-74) |
| Blasts of bone marrow (range), % | 90 (34-97.5) |
| PML-RARA/ABL (range), % | 37.6 (20.1-92.4) |
| Type of transcript (L/S/V) | 10/7/3 |
| Fibrinogen (range), mg/dL | 163 (60-429) |
| D-dimer (range), μg/L | 9 296 (2 570 to >20 000) |
| Cytogenetics, no. (%) | |
| Solo t (15;17) | 15 (75) |
| Others | 5 (25) |
| Induction treatment | |
| Live damage, no. (%) | |
| 1 grade | 2 (10) |
| 2 grade | 7 (35) |
| 3-4 grade | 0 (0) |
| Differentiation syndromes, no. (%) | |
| Moderate | 4 (20) |
| Severe | 3 (15) |
| Platelet infusion (range), U | 5 (1-18) |
| Red blood infusion (range), U | 8 (0-12) |
| Hospital days (range) | 25 (4-37) |
| Achieving hematologic CR, no. (range) | 20 (100) |
| Days to achieving hematologic CR (range) | 30 (28-55) |
| Postremission follow-up | |
| Achieving CMR, no. (%) | 20 (100) |
| Days to achieving CMR (range) | 90 (42-132) |
| Continue CMR, no. (%) | 18 (90) |
| Molecular relapse, no. (%) | 2 (10) |
| Hematologic relapse, no. (%) | 0 (0) |
L/S/V, long/short/variant.